<SEC-DOCUMENT>0001615774-18-012345.txt : 20181109
<SEC-HEADER>0001615774-18-012345.hdr.sgml : 20181109
<ACCEPTANCE-DATETIME>20181109075628
ACCESSION NUMBER:		0001615774-18-012345
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20181109
FILED AS OF DATE:		20181109
DATE AS OF CHANGE:		20181109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		181171404

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>s113908_6k.htm
<DESCRIPTION>FORM 6K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Month of November 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: 001-38104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>IMMURON LIMITED</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Level 3, 62 Lygon Street, Carlton
South, Victoria, 3053, Australia</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
&nbsp;Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yes <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMURON LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immuron Limited (the &ldquo;Company&rdquo;) published three
announcements (the &ldquo;Public Notices&rdquo;) to the Australian Securities Exchange on November 09, 2018 titled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD>&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif; color: windowtext">NASH clinical trial presentation and continued
revenue growth&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of the Public Notice is attached
as an exhibit to this report on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report on Form 6-K (including the
exhibit hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the
&ldquo;Exchange Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended,
except as shall be expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding-right: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 91%; border-bottom: black 1pt solid; padding-right: 5.4pt"><BR>
<FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><A HREF="s113908_ex99-1.htm">99.1</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt"><FONT STYLE="font-size: 10pt"><A HREF="s113908_ex99-1.htm">NASH clinical trial presentation and continued revenue growth</A> </FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><IMG SRC="img001_v1.jpg" ALT="-s- Phillip Hains"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date:&nbsp;&nbsp;November 09, 2018</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Phillip Hains</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Phillip Hains</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Company Secretary</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>

    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>s113908_ex99-1.htm
<DESCRIPTION>EXHIBIT 99-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="img002_v1.jpg" ALT="(IMMURON LIMITED)"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NASH clinical trial presentation and
continued revenue growth</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Key Highlights:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Professor Arun Sanyal to present IMM-124E
NASH clinical trial results at the Liver Meeting in San Francisco</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: windowtext">Travelan<SUP>&reg;
                                         </SUP>on display at HealthEd</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Australian
                                         Travelan<SUP>&reg;</SUP> sales continue to grow, with a Q1 CY19 figure of $340K AUD.
                                         This represents a 3% increase from the same period last year.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
                                         the month of September, Australian Travelan<SUP>&reg;</SUP> sales reached $142K AUD representing
                                         a 20% increase on the same month of last financial year.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Global Immuron Limited sales for Q1 2019
reached $482K AUD which is a 2% increase on the same quarter of last financial year.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext">Melbourne,
Australia, November 9, 2018: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian microbiome biopharmaceutical company focused
on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated diseases, today announced </FONT>that
the IMM-124E NASH clinical study findings will be presented by Professor Arun Sanyal at the American Association for the study
of Liver Disease which will be held in San Francisco, California during the 9<SUP>th</SUP> &ndash; 13<SUP>th</SUP> of November
2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The presentation entitled &ldquo;IMM-124E
Improves Metabolic Endotoxemia and Markers of Liver Injury in Non-Alcoholic Steatohepatitis&rdquo; will be on the 11<SUP>th</SUP>
of November 2018 at the Novel Therapeutics for NASH session. A copy of the presentation will be made available on Immuron&rsquo;s
website at www.immuron.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Travelan was on display at HealthEd, the
Australian General Practitioner conference series, in Sydney, Melbourne and Brisbane. At these events, Dr. Bernie Hudson, a respected
key opinion leader in Travel Medicine, presented the latest research on travellers&rsquo; diarrhoea to an audience of over 2,000
medical professionals. Key research data on Travelan<SUP>&reg;</SUP> and its efficacy was included in this educational piece.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company is pleased to report the sales
results of its commercially available and over-the-counter gastrointestinal and digestive health supplement Travelan<SUP>&reg;</SUP>,
for the fiscal year first quarter ending on September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Australian Travelan<SUP>&reg;</SUP> sales
reached $340K AUD in the first quarter of CY19, compared to $330K in the same period of last financial year. In the month of September
2018, Australian Travelan sales climbed to $142K AUD, showing a strong 20% increase from the same month of last financial year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border-top: Black 1pt solid; padding-top: 8pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Level
                                         3, 62 Lygon Street,</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: gray"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carlton
        South, Victoria</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: gray"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">AUSTRALIA
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3053</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; padding-top: 8pt"><P STYLE="color: gray; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><U>www.immuron.com</U></FONT></P>
        <P STYLE="color: gray; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
        <P STYLE="color: gray; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>
        <P STYLE="color: gray; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">ABN:
        80 063 114 045</FONT></P>
        <P STYLE="color: gray; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P></TD>
    <TD STYLE="width: 36%; border-top: Black 1pt solid; padding-top: 8pt"><P STYLE="color: gray; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Phone:&nbsp;&nbsp;&nbsp;&nbsp;
                                         + 61 (0)3 9824 5254</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Facsimile:
        + 61 (0)3 9822 7735</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; padding-left: 5.4pt; text-align: right; padding-bottom: 3pt">
        <IMG SRC="img003_v1.jpg" ALT="">
</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Global Immuron Limited revenue for Q1 CY2018,
reached $482K AUD before rebates, compared to $475K last financial year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext">Immuron
CEO Jerry Kanellos states &ldquo;we are pleased that Professor Arun Sanyal will be sharing our clinical study findings at this
important meeting. </FONT>The company&rsquo;s focus since reporting the topline results of the study in March this year has been
on completing the final clinical study report and we are currently working with our contract research organization partners to
complete the final analysis of the data generated, and additional tests currently being performed. The final clinical study report
should be completed by the end of this year and the plan is to submit it in the new year according to the FDA Code of Federal Regulations
(42 CFR Part 11) &ndash; Clinical Trials Registration and Result Information Submission guidelines.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - END - - -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%">
        <P STYLE="color: #0079C1; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>COMPANY CONTACT:</B></P>
        <P STYLE="color: #0079C1; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="color: #231F20; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Jerry Kanellos</B></P>
        <P STYLE="color: #231F20; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="color: #231F20; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P>
        <P STYLE="color: #231F20; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="color: #231F20; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ph: +61 (0)3 9824 5254</P>
        <P STYLE="color: #231F20; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="color: #231F20; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">jerrykanellos@immuron.com</P>
        <P STYLE="color: #231F20; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="width: 37%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0079C1"><B>AUS INVESTOR RELATIONS:</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0079C1">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20"><B>Peter Taylor</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">NWR Communications</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">Ph: +61 (0)4 1203 6231</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">peter@nwrcommunications.com.au</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="width: 31%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0079C1"><B>USA INVESTOR RELATIONS:</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0079C1">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dave Gentry - CEO </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RedChip Companies, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US Ph: +1 (407) 491 4498</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">dave@redchip.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20"><B>ABOUT IMMURON:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron Limited (ASX: IMC, NASDAQ: IMRN),
is an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal
antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a unique and safe technology platform
that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan<SUP>&reg;</SUP> for the
prevention of Travelers&rsquo; Diarrhea and its lead clinical candidate, IMM-124E, is in Phase II clinical trials for <B>Non-Alcoholic
Steatohepatitis </B>(NASH), <B>Severe Alcoholic Hepatitis </B>(SAH) and Pediatric <B>Nonalcoholic Fatty Liver Disease </B>(NAFLD).
Immuron&rsquo;s second clinical stage asset, IMM-529, is targeting <B>Clostridium <I>difficile </I>Infections </B>(CDI). These
products together with the Company&rsquo;s other preclinical immunotherapy pipeline products targeting immune-related diseases
currently under development, will meet a large unmet need in the global immunotherapy market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information visit: http://www.immuron.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20"><B>FORWARD-LOOKING STATEMENTS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231F20"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product
development programs and any other statements that are not historical facts. Forward-looking statements are based on management&rsquo;s
current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial
condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include:
risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and
relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and
completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers;
our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described
in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on
which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>





<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 2</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P></TD></TR></TABLE><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>

    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img001_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img001_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 10 \ P$1  (1 0,1 ?_$ '$   $$ @,!
M       %!P@) P0!!@H+ 0$                     $   !@$# @4#! $%
M       ! @,$!08' !$($A0A$Q46"3$B,D$C%QAQ48&14B01 0
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@_M6_8]GY79]GY1.V[7R/V>V\GIZ.C[>G;;PT&UH/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img002_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img002_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 4 $. P$1  (1 0,1 ?_$ .    ,!  (" P$
M       )"@@'"P,% 00& @$  @,!  ,!              <&" D% 0,$ A
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M$<=K'BS)<P[L-]X^2L96T+%(K"XDY^@S#(SJH.I-P<PK.Y&+3;+,55C;F5!
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M!!.YDL-T_1YC"3LDHK(Y+LC)S8K5D2S'>G/8GE>CE5VX2'D/CG*X?N5B(F7
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MQ3Y +;4A+NV4>R2CIOZ Z">L3QQ\2V(]F'8<D>%_N['%:&+B++^",1QL^NS
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M39J*0= F \\>R8]I*)[=ITW3\D>RX6]BS*W(>@PF5\VWY?!=2M<>C*U&K1\
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MZS'R2[5%]O\ 67BJ45/U-2XX2?ZRB0/0!( =@ $7\L-M9L]EI;73@)9880@
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MBB^[E'UHW\!<55\/?\<+^KU_"1%N&L](NS$:'O"W[Y>-_H_0?RWN.K\>%?\
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M$@"I"RJ7GD$3]R)[^%7UB''_ .E$E\MI/5D.1?NCK_J5/Q28AF$?>11?6O\
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M&F#Q8=;F9E+;LTAQN?1*E!78=_6,CVOCSWP\SMC8_OR7(Z<@W8@Q>,I[(D/
MU9TB(=!OC5XSFF+.2:F#[OS#* 8/2 Z85!E_A<QU8N]K3:TU21N&VG<6X#U&
MT*2H@^24I0LKKA7B\RE'T/>#=ET:_54%/I0V1VA1"TI*?SISAEG;W[(#'#EJ
MK^9^5DA7;G<:\NVEZEBB!WD:76YQN?S6LQ9Y)PDF2U2<<J '0;)I@Q26 #F%
M80#9,\N>)JJR>A>QO"$NTMI>&UVH7)+[B>U" G^[0KH==Q3IIK#UX3\)=-BE
MP9RKD-;59>&B%M4R?6:;6.BG5'1U2>J4@; K4E4@!0\Z1%=JY;E$"BLW61*(
M[]("HF8@".WCL CJI"%;5A7D(,796G<@I\HE$R>!.Q3G+$G)[&V=Y?.&*9:#
MI.7RY'>P4=#6\DL]C@L#R8&-:KN6Q&A7ODN )UG$"=0#\&K<9-XCK#?<+J<7
M8MM6W5/T/R<.EQLI!VA.XI Z:=!K%:;!P3=[1E=-D3U?2K88JN^[M+2P9%15
M(*GUU[=(ITU46+,0:((E]JO8ASM7^35?SFXSGB9S!P^=V66%H1&&MY)9:);7
M+\I3Q:2QVHLPD3-?P8&$?*\SQWVU;NN\1U@J\)=Q=-MJQ5.6TTP65M[ KN]F
MZ4YRGK+K%9*7@F\4^5MY":VF+**\/[ EP*EOWRG*4_Q14#MX;?:V_P"S51(L
MW'SH@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!
MH@@T01FSC=RPPYRNCLBRF'9.<DVF+<B36+;<:<KDG73MK=7RI&DFS).322-(
M,B L7H<);I'^ =2S+,*OV%NTK-]0VA=92HJ&MBTKFTN>TG;[)TU2=1$=QW*;
M1E+=0[:%+4BEJ%,N;D*1)Q/4"?4><:1I/43B11F#C]R^PIR:Q5;\S8HE9Z1H
MU'LELJ=@=S-:E8&01F:4P9R4\DVBY%%)V[01:ODQ34( D5$1 HB(#J7Y-@V0
M8C>6+#>D-IN-0RVX@(<2M)2Z2E$U),@209@].V(U8<LLV26MZ\6M3BJ)AQ:%
M%2%).YL JDDZD2(D1UC\EQ#Y[<<.<+.Y/< V.>F H9X$MB:V2K2]2?HDLC=Z
MYBW#1E-(H+O6IR,%"G43 2)GZ2F$!,&_VYQQME7'CK#63---FI"]A;<2Z#W9
M 4"4$@'UA('4C7LCY<3SG'LT0\Y8G'%A@IWA:%-GUP2D@*D2-#,CI'*?)/DG
MBGB=BB8S1F>7D(:C0CZ(C';F)B'L]*+/YQ\G'QS5C$1Q%7KU95PKXE3*(E(
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0JI/9-*09:3AEFE1#$C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img003_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img003_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ '0!> P$1  (1 0,1 ?_$ *0   $% 0$!
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M%VKHL<Q*Y8MQ:,G!6C<%V;42]@MFJP)@HW;B7P[""!>/AT<KI24%2I%&)$3
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8SNM-%W';SJDX@E7:RQY9YU<G6._%K__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
